| Patent application number | Description | Published |
|---|
| 20090069385 | Antidiabetic Oxazolidinediones and Thiazolidinediones - Pyridinyloxyphenyl and pyridinyloxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. | 03-12-2009 |
| 20100168164 | Antidiabetic Oxazolidinediones and Thiazolidinediones - Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. | 07-01-2010 |
| Patent application number | Description | Published |
|---|
| 20090053316 | NANOCLUSTERS FOR DELIVERY OF THERAPEUTICS - The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention. | 02-26-2009 |
| 20090081295 | NANOCLUSTERS FOR DELIVERY OF THERAPEUTICS - The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention. | 03-26-2009 |
| 20110111044 | NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention is directed to nanoparticle compositions for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid. | 05-12-2011 |
| 20110223203 | NANOCLUSTER COMPOSITIONS AND METHODS - Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm. | 09-15-2011 |
| 20110223257 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention relates to releasable fusogenic lipids and nanoparticle compositions containing the same for the delivery of oligonucleotides and methods of modulating gene expression using the same. In particular, this invention relates to releasable fusogenic lipids containing an imine linker and a zwitterionic moiety. | 09-15-2011 |
| 20110229581 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention is directed to releasable cationic lipids and nanoparticle compositions for the delivery of nucleic acids and methods of modulating an expression of a target gene using the same. In particular, the invention relates to cationic lipids including an acid labile linker, and nanoparticle compositions containing the same. | 09-22-2011 |
| 20110287262 | NANOPARTICLES, NANOCAPSULES AND NANOGELS - Acid-labile poly(N-vinyl formamide) (“PNVF”) nanocapsules were synthesized by free radical polymerization of N-vinyl formamide with optional active ingredients on the surface of silica nanoparticles. Polymerization in the presence of a novel cross-linker that contains an acid-labile ketal facilitated stable etching of silica nanoparticle templates using sodium hydroxide and recovery of PNVF nanocapsules. The formamido side group of PNVF was then hydrolyzed by extended exposure to sodium hydroxide to produce polyvinylamine (“PVAm”) nanocapsules. PNVF and PVAm nanoparticles are also synthesized that form nanogels with optional active ingredients. | 11-24-2011 |
| 20110305769 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol and its derivatives having multiple positively charged moieties via branching spacers, and nanoparticle compositions of oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid. | 12-15-2011 |
| 20110305770 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker. | 12-15-2011 |
| 20150140093 | NANOCLUSTERS COMPOSITIONS AND METHODS - Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm. | 05-21-2015 |
| Patent application number | Description | Published |
|---|
| 20100160303 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS - Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, | 06-24-2010 |
| 20120058996 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS - Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, | 03-08-2012 |
| 20120082702 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS - Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds. | 04-05-2012 |
| 20140378475 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS - Disclosed are compounds of Formula (I) | 12-25-2014 |
| Patent application number | Description | Published |
|---|
| 20100208063 | SYSTEM AND METHODS FOR IMPROVING ACCURACY AND ROBUSTNESS OF ABNORMAL BEHAVIOR DETECTION - A surveillance system improves accuracy and robustness of abnormal behavior detection of a monitored object traversing a space includes a metadata processing module, a model building module, and a behavior assessment module. The metadata processing module generates trajectory information for a monitor object and determines attributes of the monitored object. The model building module at least one of generates and updates normal motion models based on at least one of the trajectory information, the attributes, and an abnormal behavior score. The behavior assessment module generates the abnormal behavior score based on one of a plurality of methods. A first one of the plurality of methods defines wrong direction behavior. A second one of the plurality of methods defines wandering/loitering behavior. A third one of the plurality of methods defines speeding behavior. | 08-19-2010 |
| 20110205359 | VIDEO SURVEILLANCE SYSTEM - A video surveillance system is disclosed. The system includes a model database storing a plurality of models and a vector database storing a plurality of vectors of recently observed trajectories. The system includes a model building module that builds a new motion model corresponding to the motion data of the current trajectory data structure. The system generates a current trajectory data structure having motion data and abnormality scores. The system also includes a database purging module configured to determine a subset of vectors that is most similar to the current trajectory data structure based on a measure of similarity between the subset of vectors and the current trajectory data structure. The database purging module is further configured to replace one of the motion models in the model database with the new motion model based on an amount of vectors in the subset vectors the recentness of the subset of vectors. | 08-25-2011 |
| 20140112546 | Video Surveillance System - A video surveillance system is disclosed. The system includes a model database storing a plurality of models and a vector database storing a plurality of vectors of recently observed trajectories. The system includes a model building module that builds a new motion model corresponding to the motion data of the current trajectory data structure. The system generates a current trajectory data structure having motion data and abnormality scores. The system also includes a database purging module configured to determine a subset of vectors that is most similar to the current trajectory data structure based on a measure of similarity between the subset of vectors and the current trajectory data structure. The database purging module is further configured to replace one of the motion models in the model database with the new motion model based on an amount of vectors in the subset vectors the recentness of the subset of vectors. | 04-24-2014 |
| 20140119608 | System and Methods for Improving Accuracy and Robustness of Abnormal Behavior Detection - A surveillance system which improves accuracy and robustness of abnormal behavior detection of a monitored object traversing a space includes a metadata processing module, a model building module, and a behavior assessment module. The metadata processing module generates trajectory information for a monitored object and determines attributes of the monitored object. The model building module generates and updates normal motion models based on at least one of the trajectory information, the attributes, and an abnormal behavior score. The behavior assessment module generates the abnormal behavior score based on one of a plurality of methods. A first one of the plurality of methods defines wrong direction behavior. A second one of the plurality of methods defines wandering/loitering behavior. A third one of the plurality of methods defines speeding behavior. | 05-01-2014 |
| Patent application number | Description | Published |
|---|
| 20110082196 | THEAFLAVIN COMPOSITIONS, RELATED PROCESSES AND METHODS OF USE - A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form. | 04-07-2011 |
| 20110082198 | THEAFLAVIN COMPOSITIONS, PRODUCTION, AND METHODS TO CONTROL PHYSIOLOGICAL DISORDERS IN MAMMALS - A process for producing a purified extract comprising between about 40% and about 90% theaflavins is provided. Purified theaflavin extract produced by the disclosed process is provided which comprises less than about 5% TF1, between about 10% and about 60% TF2a, between about 5% and about 35% TF2b, and between about 10% and about 65% TF3. Individual dosage compositions are provided for the control of a physiological disorder comprising about 5% to about 95% theaflavins in a pharmaceutically acceptable vehicle or a dietary supplement vehicle. Further individual dosage compositions are provided which comprise an effective amount of substantially only one theaflavin species selected from the group consisting of TF1, TF2a, TF2b, and TF3. Individual dosage compositions are provided which comprise an effective amount of substantially only two theaflavin species selected from the group consisting of TF1 and TF2a, TF1 and TF2b, TF1 and TF3, TF2a and TF2b, TF2a and TF3, TF2b and TF3. Methods of treatment of human physiological disorders are provided which comprise administering oral dosage forms of the compositions. | 04-07-2011 |
| 20130023583 | Theaflavin Compositions, Related Processes and Methods of Use - A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form. | 01-24-2013 |
| 20130023584 | Theaflavin Compositions, Related Processes and Methods of Use - A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form. | 01-24-2013 |
| 20130296417 | Theaflavin Compositions, Production, and Method to Control Physiological Disorders in Mammals - A process for producing a purified extract comprising between about 40% and about 90% theaflavins is provided. Purified theaflavin extract produced by the disclosed process is provided which comprises less than about 5% TF1, between about 10% and about 60% TF2a, between about 5% and about 35% TF2b, and between about 10% and about 65% TF3. Individual dosage compositions are provided for the control of a physiological disorder comprising about 5% to about 95% theaflavins in a pharmaceutically acceptable vehicle or a dietary supplement vehicle. Further individual dosage compositions are provided which comprise an effective amount of substantially only one theaflavin species selected from the group consisting of TF1, TF2a, TF2b, and TF3. Individual dosage compositions are provided which comprise an effective amount of substantially only two theaflavin species selected from the group consisting of TF1 and TF2a, TF1 and TF2b, TF1 and TF3, TF2a and TF2b, TF2a and TF3, TF2b and TF3. Methods of treatment of human physiological disorders are provided which comprise administering oral dosage forms of the compositions. | 11-07-2013 |
| Patent application number | Description | Published |
|---|
| 20080247819 | Capped and/or beveled jet blast resistant vehicle arresting units, bed and methods - Aircraft arresting beds at ends of runways may be subject to damaging effects of jet blast phenomena. Arresting units for that and other applications and which are resistant to such effects are described, with related methods. | 10-09-2008 |
| 20100071474 | Field Strength Test Devices and Methods for Installed Engineered Material Arresting Systems - Embodiments of the present invention provide field test devices and methods for testing the compressive gradient strength of installed vehicle arresting systems, such as those installed on airport runways. Current methods of testing such arresting systems are conducted on sample materials in-house, and these methods are not applicable or useful when tests need to be conducted on currently-installed systems in the field. | 03-25-2010 |
| 20100254762 | CAPPED AND/OR BEVELED JET BLAST RESISTANT VEHICLE ARRESTING UNITS, BED AND METHODS - Aircraft arresting beds at ends of runways may be subject to damaging effects of jet blast phenomena. Arresting units for that and other applications and which are resistant to such effects are described, with related methods. | 10-07-2010 |
| 20110020062 | VEHICLE INCURSION INHIBITORS - Detailed are systems and techniques for protecting structures from vehicular attack. The systems incorporate deformable materials sufficient to disable or otherwise inhibit certain vehicular traffic yet support weights and weight distributions typically associated with pedestrian or other non-threat traffic. Bodies of deformable materials further may include rigid structures or vehicle-immobilization devices. | 01-27-2011 |
| 20150034439 | FRANGIBLE COMPONENTS AND THEIR USE IN A SYSTEM FOR ENERGY ABSORPTION - Embodiments of the present invention provide a core of individual components having properties such that a system assembled from the components absorbs the kinetic energy of a moving vehicle. The components may be interlocking components. The components may be manufactured of ceramic or polymeric composite or other materials that are strong enough to absorb the vehicle's energy and help stop the vehicle safely by the system's ability to crush or deform upon impact, and not so strong that it causes the vehicle to crumple against the barrier. In one particular embodiment, the components may be modified packing elements that are traditionally used in gas to liquid columns. | 02-05-2015 |
| 20150247298 | MACRO-PATTERNED MATERIALS AND STRUCTURES FOR VEHICLE ARRESTING SYSTEMS - Embodiments of the present disclosure relate generally to macro-patterned materials and methods of their use in connection with vehicle arresting systems. Certain embodiments provide 3-D folded materials, honeycombs, lattice structures, and other periodic cellular material structures, that can be used for arresting vehicles. The materials can be engineered to have properties that allow them to reliably crush in a predictable manner under pressure from a vehicle. The materials can be formed into various shapes and combined in various ways in order to provide the desired properties. | 09-03-2015 |
| Patent application number | Description | Published |
|---|
| 20080206101 | Fluidic array devices and systems, and related methods of use and manufacturing - The instant application provides a fluidic array device having an elastomeric body that provides easy fluidic control of the device. The elastomeric body may include plurality of intersecting row and column channels. Reactions may occur at the intersection spots formed by the intersecting channels. Pinching applied at suitable locations along the channels enables the channels to be opened or closed, and thus provides control of fluids pumped through the device. The surfaces of the channels and intersection spots may be engineered to have certain properties. In particular, the intersection spots may be nanoengineered to have surface properties differing from those of the channels, and thus reactions may be selectively controlled to occur only, or highly preferentially, in the intersection spots. | 08-28-2008 |
| 20090056094 | Piezoelectric composite nanofibers, nanotubes, nanojunctions and nanotrees - Piezoelectric nanostructures, including nanofibers, nanotubes, nanojunctions and nanotrees, may be made of piezoelectric materials alone, or as composites of piezoelectric materials and electrically-conductive materials. Homogeneous or composite nanofibers and nanotubes may be fabricated by electrospinning. Homogeneous or composite nanotubes, nanojunctions and nanotrees may be fabricated by template-assisted processes in which colloidal suspensions and/or modified sol-gels of the desired materials are deposited sequentially into the pores of a template. The electrospinning or template-assisted fabrication methods may employ a modified sol-gel process for obtaining a perovskite phase in the piezoelectric material at a low annealing temperature. | 03-05-2009 |
| 20100084791 | METHODS OF MANUFACTURING FIBERS - A method of fabricating micro- and nano-scale fiber comprises: spreading micro- and nano-scale particles into a liquid or fluid-like material prior to forcing portions of the liquid or fluid-like material that surround the particles to depart from the original liquid or fluid-like environment by using a force field; stretching to elongate the portions of the liquid or fluid-like material until the free ends of the stretched portions stop motion to complete fiber or fiber-like structures in micro- and nano-scales. | 04-08-2010 |
| 20110209820 | Piezoelectric composite nanofibers, nanotubes, nanojunctions and nanotrees - Piezoelectric nanostructures, including nanofibers, nanotubes, nanojunctions and nanotrees, may be made of piezoelectric materials alone, or as composites of piezoelectric materials and electrically-conductive materials. Homogeneous or composite nanofibers and nanotubes may be fabricated by electrospinning. Homogeneous or composite nanotubes, nanojunctions and nanotrees may be fabricated by template-assisted processes in which colloidal suspensions and/or modified sol-gels of the desired materials are deposited sequentially into the pores of a template. The electrospinning or template-assisted fabrication methods may employ a modified sol-gel process for obtaining a perovskite phase in the piezoelectric material at a low annealing temperature. | 09-01-2011 |
| 20110210650 | Piezoelectric composite nanofibers, nanotubes, nanojunctions and nanotrees - Piezoelectric nanostructures, including nanofibers, nanotubes, nanojunctions and nanotrees, may be made of piezoelectric materials alone, or as composites of piezoelectric materials and electrically-conductive materials. Homogeneous or composite nanofibers and nanotubes may be fabricated by electrospinning. Homogeneous or composite nanotubes, nanojunctions and nanotrees may be fabricated by template-assisted processes in which colloidal suspensions and/or modified sol-gels of the desired materials are deposited sequentially into the pores of a template. The electrospinning or template-assisted fabrication methods may employ a modified sol-gel process for obtaining a perovskite phase in the piezoelectric material at a low annealing temperature. | 09-01-2011 |
| Patent application number | Description | Published |
|---|
| 20090202479 | Method for modulating immune responses using stem cells and cytokines - The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD). | 08-13-2009 |
| 20140154207 | KIT CONTAINING STEM CELLS AND CYTOKINES FOR USE IN ATTENUATING IMMUNE RESPONSES - The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD). | 06-05-2014 |
| 20150313946 | METHODS MODULATING IMMUNOREGULATORY EFFECT OF STEM CELLS - The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs). | 11-05-2015 |
| Patent application number | Description | Published |
|---|
| 20090048280 | Process for the preparation of substituted phenylalanines - Intermediates and synthetic processes for the preparation of substituted phenylalanine-based compounds (e.g., of Formula I) are disclosed: | 02-19-2009 |
| 20090118505 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENYLALANINES - Intermediates and synthetic processes for the preparation of substituted phenylalanine-based compounds (e.g., of Formula I) are disclosed: | 05-07-2009 |
| 20100087433 | Methods of inhibiting tryptophan hydroxylase - Compounds, compositions and methods of treating serotonin-mediated diseases and disorders are disclosed. | 04-08-2010 |
| 20100280054 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE - Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: | 11-04-2010 |
| 20110130564 | COMPOUNDS USEFUL IN THE PREPARATION OF TRYPTOPHAN HYDRROXYLASE INHIBITORS - Intermediates and synthetic processes for the preparation of substituted phenylalanine-based compounds (e.g., of Formula I) are disclosed: | 06-02-2011 |
| 20120041008 | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use - Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders: | 02-16-2012 |
| 20120157484 | TRYPTOPHAN HYDROXYLASE INHIBITORS - Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: | 06-21-2012 |
| 20130023515 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS - Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. | 01-24-2013 |
| 20130040929 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS - Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. | 02-14-2013 |
| 20130059830 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS - Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. | 03-07-2013 |
| 20130143859 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS - Compounds of structural formulas I-1 and I-2 are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. | 06-06-2013 |
| 20140235628 | Inhibitors of the Renal Outer Medullary Potassium Channel - This invention relates to compounds having structural Formula I: | 08-21-2014 |
| 20140275020 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I having the following general structure: | 09-18-2014 |
| 20140288042 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I having the following general structure: | 09-25-2014 |
| 20140309213 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I-VI having the following general structure: | 10-16-2014 |
| 20150299198 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula I | 10-22-2015 |
| Patent application number | Description | Published |
|---|
| 20090312331 | PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPY- LPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN - Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. | 12-17-2009 |
| 20120108594 | PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPY- LPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN - Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. | 05-03-2012 |
